| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424577000 | Hemic or immune system (e.g., hematopoietic system, bone marrow cells, etc.) | 15 |
| 20100297255 | MALLEABLE IMPLANTS CONTAINING DEMINERALIZED BONE MATRIX - Described are malleable medical compositions such as pastes or putties that include solids combined with a liquid carrier. The solids include particulate collagen and particulate demineralized bone matrix. The liquid carrier includes an aqueous medium comprising a polysaccharide. Also described are methods for making and using such medical compositions. | 11-25-2010 |
| 20130136799 | MONITORING HEALTH AND DISEASE STATUS USING CLONOTYPE PROFILES - There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers. | 05-30-2013 |
| 20130316014 | METHODS FOR PREDICTING PROGNOSIS OF A SUBJECT WITH A MYELOID MALIGNANCY - One aspect of the present disclosure includes a method for predicting the prognosis of a subject with a myeloid malignancy. One step of the method includes obtaining a biological sample from the subject. Next, at least one mutation in a spliceosome-associated protein, or a polynucleotide encoding the spliceosome-associated protein that results in defective splicing can be detected in the biological sample. The presence of at least one mutation in the spliceosome-associated protein, or a polynucleotide encoding the spliceosome-associated protein, is indicative of the subject's prognosis. | 11-28-2013 |
| 20140023723 | Decellularized Extracellular Matrix - Methods for producing compositions of decellularized extracellular matrix (DM) tissue culture are described. The compositions can be used for coating supports such as tissue culture substrates, osteogenic gels, and medical devices. | 01-23-2014 |
| 20140065240 | METHODS AND COMPOSITIONS RELATING TO MESENCHYMAL STEM CELL EXOSOMES - The invention provides compositions comprising mesenchymal stem cell (MSC) derived exosomes, and methods of their use in subjects having certain lung diseases including inflammatory lung disease. | 03-06-2014 |
| 20140134265 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY - Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections. | 05-15-2014 |
| 20150093447 | STEM CELL IDENTIFICATION AND PURIFICATION METHOD - The invention provides a composition comprising enriched extracellular vesicles, wherein the extracellular vesicles express VSEL markers. The extracellular vesicles are used to treat or regenerate damages or injured tissue in a subject. | 04-02-2015 |
| 20160025747 | USE AND TREATMENT OF DI-AMINO ACID REPEAT-CONTAINING PROTEINS ASSOCIATED WITH ALS - Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein. | 01-28-2016 |
| 20160114078 | TREATMENT OF SKELETAL VOIDS WITH IMPLANTABLE SUBSTRATE HYDRATED WITH BONE MARROW CONCENTRATE - The invention is directed to a bone void filler comprising a scaffold or matrix. The scaffold or matrix may include a porous inorganic matrix component. The bone void filler may include a cellular component containing cells, some of which are capable of making extracellular matrix resembling native bone tissue. The bone void filler may include an organic matrix, such as, an organic biopolymer that aids in cell retention and renders the scaffold or matrix moldable. The bone void filler may include growth factors and/or cytokines. The bone void filler may include a clotting agent. | 04-28-2016 |
| 20160374989 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR - Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders. | 12-29-2016 |
| 424578000 | Lymphoid tissue (e.g., adenoid, lymph node, etc.) | 5 |
| 20140087002 | Autologous Lymph Node Transfer In Combination With VEGF-C Or VEGF-D Growth Factor Therapy to Treat Lymphedema And To Improve Reconstructive Surgery - Materials and methods are provided to improve survival of lymph nodes and integration of lymph nodes into a lymphatic network, following lymph node transplantation. The treatment or prevention of lymphedema is also addressed. A method of lymph node transfer includes transferring or transplanting a lymph node or lymph node fragment in a mammalian subject; and administering a composition comprising an agent selected from the group consisting of Vascular Endothelial Growth Factor C (VEGF-C) polynucleotides, VEGF-C polypeptides, Vascular Endothelial Growth Factor D (VEGF-D) polynucleotides, and VEGF-D polypeptides to a perinodal site within 20 cm of the lymph node or lymph node fragment. In certain embodiments, the agent is present in the composition in an amount effective to promote survival of the lymph node and integration of the lymph node into a lymphatic network in the mammalian subject, at the site of transfer or transplantation. | 03-27-2014 |
| 424580000 | Thymus gland | 4 |
| 20090041854 | PARATHYROID AND THYMUS TRANSPLANTATION IN DIGEORGE SYNDROME SUBJECTS - A method of treating hypoparathyroidism in a human DiGeorge syndrome subject comprises (a) implanting thymus tissue into the subject in an amount effective to treat the DiGeorge syndrome; and (b) implanting, preferably concurrently implanting, parathyroid tissue into the subject in an amount effective to treat the hypoparathyroidism. | 02-12-2009 |
| 20110020464 | METHODS OF TREATMENT USING THYMUS-DERIVED COMPOSITIONS - Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to impaired physical vigor or aptitude, and aging and/or age-related conditions (arthritis, mobility deficits, loss of appetite, etc.). Additional aspects provide methods for building muscle mass, for reducing exercise recovery period, or for sustaining exercise intensity. Particular aspects relate to preparation of | 01-27-2011 |
| 20110020465 | METHODS OF TREATMENT OF GOUT USING THYMUS-DERIVED COMPOSITIONS - Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to arthritis and/or arthritis-related conditions, including: gout, rheumatoid arthritis (RA), osteoarthritis (OA), and pseudogout, and/or inflammation resulting from any of the conditions Additional aspects provide methods for combination or adjunctive therapies (with anti-inflammatories, etc.). Methods to modulate immune response are also encompassed. | 01-27-2011 |
| 20140072651 | METHODS OF TREATMENT USING THYMUS-DERIVED COMPOSITIONS - Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to impaired physical vigor or aptitude, and aging and/or age-related conditions (arthritis, mobility deficits, loss of appetite, etc.). Additional aspects provide methods for building muscle mass, for reducing exercise recovery period, or for sustaining exercise intensity. Particular aspects relate to preparation of | 03-13-2014 |
